Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Exelixis stock price, quote, forecast and news

EXEL
US30161Q1040
936718

Price

25.96
Today +/-
-0.25
Today %
-1.07 %
P

Exelixis stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Exelixis stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Exelixis stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Exelixis stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Exelixis's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Exelixis Stock Price History

DateExelixis Price
9/27/202425.96 undefined
9/26/202426.24 undefined
9/25/202426.06 undefined
9/24/202426.28 undefined
9/23/202426.36 undefined
9/20/202426.42 undefined
9/19/202426.83 undefined
9/18/202426.82 undefined
9/17/202427.60 undefined
9/16/202427.47 undefined
9/13/202426.46 undefined
9/12/202426.31 undefined
9/11/202426.63 undefined
9/10/202426.31 undefined
9/9/202425.51 undefined
9/6/202425.15 undefined
9/5/202425.57 undefined
9/4/202425.61 undefined
9/3/202425.83 undefined

Exelixis Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Exelixis, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Exelixis from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Exelixis’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Exelixis. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Exelixis’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Exelixis’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Exelixis’s growth potential.

Exelixis Revenue, EBIT and net profit per share

DateExelixis RevenueExelixis EBITExelixis Net Income
2029e2.73 B undefined0 undefined902.69 M undefined
2028e2.73 B undefined903.89 M undefined832.45 M undefined
2027e2.59 B undefined791.83 M undefined728.35 M undefined
2026e2.32 B undefined658.97 M undefined581.7 M undefined
2025e2.1 B undefined507.45 M undefined438.07 M undefined
2024e2.09 B undefined385.63 M undefined457.4 M undefined
20231.83 B undefined170.89 M undefined207.77 M undefined
20221.61 B undefined201.5 M undefined182.3 M undefined
20211.44 B undefined286.7 M undefined231.1 M undefined
2020987.5 M undefined110.1 M undefined111.8 M undefined
2019967.8 M undefined369.5 M undefined321 M undefined
2018853.8 M undefined438.9 M undefined690.1 M undefined
2017452.5 M undefined165.9 M undefined154.2 M undefined
2016191.5 M undefined-27.2 M undefined-70.2 M undefined
201537.2 M undefined-120.4 M undefined-161.7 M undefined
201425.1 M undefined-216.9 M undefined-261.3 M undefined
201331.3 M undefined-199.5 M undefined-244.8 M undefined
201247.5 M undefined-113.2 M undefined-147.6 M undefined
2011289.6 M undefined99.6 M undefined75.7 M undefined
2010185 M undefined-58.7 M undefined-92.3 M undefined
2009151.8 M undefined-121.9 M undefined-135.2 M undefined
2008117.9 M undefined-176.4 M undefined-162.9 M undefined
2007113.5 M undefined-157 M undefined-86.4 M undefined
200698.7 M undefined-126.8 M undefined-101.5 M undefined
200576 M undefined-94 M undefined-84.4 M undefined
200452.9 M undefined-106.5 M undefined-137.2 M undefined

Exelixis Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000.010.020.040.040.050.050.080.10.110.120.150.190.290.050.030.030.040.190.450.850.970.991.441.611.832.092.12.322.592.732.73
----400.00140.0070.837.3215.911.9646.1528.9515.313.5429.0622.5256.22-83.74-34.04-19.3548.00416.22136.6588.7213.362.0745.3912.2613.5914.260.4810.3311.695.410.07
-----------------100.0096.7792.0089.1996.3496.6896.9596.5996.3596.3196.4096.01------
000000000000000000.050.030.020.030.180.440.830.930.951.381.551.76000000
-3-5-12-15-18-42-65-87-95-106-94-126-157-176-121-5899-113-199-216-120-271654383691102862011703855076587919030
----750.00-180.00-175.00-158.54-197.73-186.27-203.85-123.68-128.57-138.94-150.43-80.13-31.3534.26-240.43-641.94-864.00-324.32-14.1436.5051.3538.1611.1419.9312.489.2918.4124.1328.3930.5533.09-
-3-5-11-15-18-75-71-86-94-137-84-101-86-162-135-9275-147-244-261-161-70154690321111231182207457438581728832902
-66.67120.0036.3620.00316.67-5.3321.139.3045.74-38.6920.24-14.8588.37-16.67-31.85-181.52-296.0065.996.97-38.31-56.52-320.00348.05-53.48-65.42108.11-21.2113.74120.77-4.1632.6525.3014.298.41
1.11.21.324.13146.556.665.472.578.886.699.1105.5107.1108.5130.5160.1184.1194.3209.2250.5312312.8315318322.4324.6321.46000000
-----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Exelixis Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Exelixis is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                   
00.010.110.230.220.240.160.20.230.270.260.20.160.190.410.240.140.170.420.390.690.851.211.471.311
0.20.21.543.33.84.47.122.26.11.511.95.930.22.83.94.95.240.477.3162.8120.2160.9282.7214.8237.41
00000000000000000003.91600000
003.60000000000002.92.42.63.36.79.812.92127.533.317.32
0.40.922.93.83.24.45.46.16.27.715.114.94.418.317.315.73.85.49.31525.95757.562.267.93
00.010.120.230.230.240.160.210.260.280.270.230.180.230.430.270.170.180.470.490.91.011.451.831.621.32
5.79.523.536.532.433.535.535.632.334.736.229.415.88.56.14.92.41.42.125.756.890.7110.4149.2345.4361.98
0000000019.620.717.811.587.385.3182.3144.381.683.655.664.3157.2534.7332.3371.1756.7728.72
0.50.60.50.90.90.20.100000000000000001.71.71.32
0007.14.84.14.53.42.600000000000000000
0058.762.467.467.467.467.467.463.763.763.763.763.763.763.763.763.763.763.763.763.763.763.763.763.68
0.10.82.65.14.58.5201611.39.212.48.910.5736.523.88.355.416.7247.6185.3185.6195.9285.2468.7
0.010.010.090.110.110.110.130.120.130.130.130.110.180.160.290.240.160.150.130.170.530.870.690.781.451.62
0.010.020.210.350.340.360.290.330.40.410.40.340.360.390.720.50.320.330.60.661.421.892.142.623.072.94
                                                   
38.146.800.10.10.10.10.10.10.10.10.10.10.10.20.20.20.20.30.30.30.30.30.30.30.3
00.020.30.440.460.540.570.640.760.860.90.930.951.21.551.561.651.832.072.112.172.242.322.432.542.44
-36-54.7-130-201.2-287.4-382.1-519.4-603.8-705.3-791.7-954.5-1,089.7-1,182.1-1,106.4-1,254-1,498.8-1,767.3-1,937-1,983.1-1,829.2-880.4-559.4-447.6-216.5-34.2-173.35
-1.8-14.2-9.8-3.60.71.70.611.10.500.20-0.1-0.10.1-0.1-0.2-0.4-0.3-0.73.14.5-0.8-14.5-3.75
00000000000000000000000000
0-00.160.240.180.160.050.030.050.07-0.06-0.16-0.230.090.30.07-0.11-0.10.090.281.291.691.882.212.492.26
0.63.63.754.76.25.91.73.79.34.97.4224.49.36.46.46.69.610.911.623.624.332.733.77
006.313.113.114.818.321.630.743.752.757.152.639.142.760.957.242.653.46660.590.7115.9231.4180.1218.19
0.42.87.115.223.821.628.743.563.564.188.9103.4107.646.421.45.993.219.739.53440.465.181.9111.6142.32
001.5000030000000000000000000
1.42.35.57.18.79.910.91213.615.84339.337.74.913.211.897.80189.10000000
2.48.724.140.450.352.563.8108.8111.5132.9189.5207.2199.992.481.787.9170.452.2268.8115.1105.4142.7204.6337.6324.4394.28
2.611841.865.3101.2136.5106.9108.1105.774.740.4170.7176.6322.6335.5259.1381.4014.50.100000
00000000000000000000000000
0.92927.247.742.740.459.885.388193.6259.7218.533.720.413.78.53237.6240.629.35753.668258.7284.17
3.5131769113143.9176.9166.7193.4193.7268.3300.1389.2210.3343349.2267.6384.4237.6255.129.45753.668258.7284.17
5.921.741.1109.4163.3196.4240.7275.5304.9326.6457.8507.3589.1302.7424.7437.1438436.6506.4370.2134.8199.7258.2405.6583.1678.44
0.010.020.20.350.340.360.290.310.360.40.40.340.360.390.720.50.320.330.60.661.421.892.142.623.072.94
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Exelixis provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Exelixis's financial health and stability.

Assets

Exelixis's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Exelixis must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Exelixis after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Exelixis's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1997199819992000200120022003200420052006200720082009nullnull20102011201220132014201520162017null2018null20192020202120222023
-11-15-18-75-71-86-94-137-84-101-111-175-139-162-139-9275-147-244-261-161-70154154690690321111231182207
0124151617171716111312131210653211114789132025
000000000000000000000000-244-244711546-60-133
00551534-302942471338013380-56-264-133-10-22235-18-18-79-7967-40-39-12-13
00352163126-9-3-1542556325834415143626852288541116217268340353
000012022200100101167191919212000000000
0000000000000000010000001007413127185
-10-12-7-12-23-30-79-93-46-45-68-9-14-9-14-101-159-123-198-235-141210165165415415527209400362333
-4-2-4-15-9-5-14-12-14-11-17-15-5-15-5-1-1-2-200-1-21-21-33-33-12-30-64-27-40
-60-6-96552-1420-40-21-3121-112121-112-19-51-25914414650-2143636-297-297-587-131-42-524-26
-22-2-811458032-26-1014136-106136-106-17-50-25614614650-2125757-264-264-574-10021-49613
0000000000000000000000000000000
018-2212237341-270-3-38-3-38125-6272-13-11-4-7-185-1850000000
156812512976562968344445193205177157272222171722242423-516
16717123343211439100109840-340-34131187478-116515215-169-1699912-25-140-546
00000100374000000000000-4-6-6-7-7-9-50-39-23-29
0000000000000000000000000000000
0-5314165421-33134212112-160112-16010-2395-66-2361113232127127-4752343-161-239
-14.8-15.2-11.4-28.3-32.9-36.8-93.4-106.1-60.8-56.9-86.1-24.9-20.500-102.8-160.2-125.8-201-235.9-142208.7144.50382.40514.2178.7336.6334.9292.86
0000000000000000000000000000000

Exelixis stock margins

The Exelixis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Exelixis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Exelixis.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Exelixis's sales revenue. A higher gross margin percentage indicates that the Exelixis retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Exelixis's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Exelixis's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Exelixis's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Exelixis. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Exelixis's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Exelixis Margin History

Exelixis Gross marginExelixis Profit marginExelixis EBIT marginExelixis Profit margin
2029e96.04 %0 %33.05 %
2028e96.04 %33.11 %30.49 %
2027e96.04 %30.58 %28.13 %
2026e96.04 %28.43 %25.09 %
2025e96.04 %24.15 %20.85 %
2024e96.04 %18.44 %21.87 %
202396.04 %9.34 %11.35 %
202296.41 %12.51 %11.32 %
202196.31 %19.98 %16.1 %
202096.33 %11.15 %11.32 %
201996.58 %38.18 %33.17 %
201896.92 %51.41 %80.83 %
201796.66 %36.66 %34.08 %
201696.55 %-14.2 %-36.66 %
201589.52 %-323.66 %-434.68 %
201492.03 %-864.14 %-1,041.04 %
201396.49 %-637.38 %-782.11 %
2012100 %-238.32 %-310.74 %
201196.04 %34.39 %26.14 %
201096.04 %-31.73 %-49.89 %
200996.04 %-80.3 %-89.06 %
200896.04 %-149.62 %-138.17 %
200796.04 %-138.33 %-76.12 %
200696.04 %-128.47 %-102.84 %
200596.04 %-123.68 %-111.05 %
200496.04 %-201.32 %-259.36 %

Exelixis Stock Sales Revenue, EBIT, Earnings per Share

The Exelixis earnings per share therefore indicates how much revenue Exelixis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Exelixis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Exelixis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Exelixis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Exelixis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Exelixis Revenue, EBIT and net profit per share

DateExelixis Sales per ShareExelixis EBIT per shareExelixis Earnings per Share
2029e9.57 undefined0 undefined3.16 undefined
2028e9.57 undefined0 undefined2.92 undefined
2027e9.08 undefined0 undefined2.55 undefined
2026e8.13 undefined0 undefined2.04 undefined
2025e7.37 undefined0 undefined1.54 undefined
2024e7.33 undefined0 undefined1.6 undefined
20235.69 undefined0.53 undefined0.65 undefined
20224.96 undefined0.62 undefined0.56 undefined
20214.45 undefined0.89 undefined0.72 undefined
20203.11 undefined0.35 undefined0.35 undefined
20193.07 undefined1.17 undefined1.02 undefined
20182.73 undefined1.4 undefined2.21 undefined
20171.45 undefined0.53 undefined0.49 undefined
20160.76 undefined-0.11 undefined-0.28 undefined
20150.18 undefined-0.58 undefined-0.77 undefined
20140.13 undefined-1.12 undefined-1.34 undefined
20130.17 undefined-1.08 undefined-1.33 undefined
20120.3 undefined-0.71 undefined-0.92 undefined
20112.22 undefined0.76 undefined0.58 undefined
20101.71 undefined-0.54 undefined-0.85 undefined
20091.42 undefined-1.14 undefined-1.26 undefined
20081.12 undefined-1.67 undefined-1.54 undefined
20071.15 undefined-1.58 undefined-0.87 undefined
20061.14 undefined-1.46 undefined-1.17 undefined
20050.96 undefined-1.19 undefined-1.07 undefined
20040.73 undefined-1.47 undefined-1.89 undefined

Exelixis business model

Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.com.

Exelixis SWOT Analysis

Strengths

1. Strong product portfolio: Exelixis Inc offers a diverse range of innovative pharmaceutical products, giving the company a competitive edge in the market.

2. Robust research and development (R&D) capabilities: The company has invested heavily in R&D, allowing them to continuously develop new and improved drugs.

3. Established reputation: Exelixis Inc has built a solid reputation for delivering high-quality products and has gained the trust of healthcare professionals worldwide.

Weaknesses

1. Reliance on key products: The company's revenue heavily relies on a few key products, which could pose a risk if sales decline or face regulatory issues.

2. Limited geographic presence: Exelixis Inc primarily operates in select markets, limiting its potential customer base and growth opportunities.

3. Vulnerability to market competition: Intense competition from rival pharmaceutical companies could impact market share and profitability.

Opportunities

1. Expansion into new markets: Exelixis Inc can explore untapped markets or enter into strategic partnerships to reach a wider customer base.

2. Growing demand for innovative therapies: With rising healthcare needs and advancements in medical science, there is an increasing demand for new and effective treatments.

3. Emerging markets: The company can take advantage of opportunities offered by emerging markets, where healthcare infrastructure and access to medicines are improving.

Threats

1. Stringent regulatory environment: Regulatory changes or delays in obtaining approvals may impact the company's ability to launch new products or expand into new markets.

2. Intellectual property challenges: Exelixis Inc may face patent infringements or challenges, potentially affecting the exclusivity and profitability of its products.

3. Economic uncertainties: Global economic fluctuations, healthcare reforms, or changes in insurance coverage could impact consumer spending on pharmaceuticals.

Exelixis Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Exelixis Revenue by Segment

Segmente202320222021202120202018
Net product revenues1.63 B USD1.4 B USD741.55 M USD1.08 B USD--
License revenues20.67 M USD11.34 M USD61.12 M USD26.06 M USD--
Collaboration services revenues13.54 M USD12.9 M USD20.56 M USD13.67 M USD--
Cotellic----5.68 M USD5.56 M USD
Net product revenues-----619.28 M USD
Collaboration revenue-----270.43 M USD
MINNEBRO----100,000 USD-
Gross product revenues2.27 B USD1.95 B USD962.59 M USD1.45 B USD--
Total collaboration revenues201.33 M USD209.82 M USD245.99 M USD357.71 M USD207.83 M USD-
Net product revenues----759.95 M USD-
Discounts and allowances-643.65 M USD-549.93 M USD-221.04 M USD-375.66 M USD--
CABOMETYX--718.69 M USD1.05 B USD--
COMETRIQ--22.86 M USD23.21 M USD--
CABOMETYX----733.42 M USD-
COMETRIQ----26.53 M USD-
Gross product revenues----957.62 M USD-
License revenues----161.3 M USD-
Research and development service revenues----49.97 M USD-
MINNEBRO--1.3 M USD---
Other collaboration revenues-----3.44 M USD-
Discounts and allowances-----197.67 M USD-
Cotellic16.9 M USD12.5 M USD-12.1 M USD--

Exelixis Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Exelixis Revenue by Segment

DateEuropeJapanRest of the worldU.S
2023144.97 M USD39.49 M USD-1.65 B USD
2022168.59 M USD28.73 M USD-1.41 B USD
2021151.63 M USD83.02 M USD-752.89 M USD
2021302.07 M USD43.5 M USD-1.09 B USD
2020152.77 M USD44.76 M USD-770.24 M USD
2018182.88 M USD-38.02 M USD632.93 M USD

Exelixis Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Exelixis historical P/E ratio, EBIT, and P/S ratio.

Exelixis shares outstanding

The number of shares was Exelixis in 2023 — This indicates how many shares 321.464 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Exelixis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Exelixis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Exelixis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Exelixis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Exelixis.

Exelixis latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.31 0.77  (148.95 %)2024 Q2
3/31/20240.24 0.2  (-17.73 %)2024 Q1
12/31/20230.22 0.27  (24.6 %)2023 Q4
9/30/20230.1 0  (-100 %)2023 Q3
6/30/20230.16 0.25  (53.19 %)2023 Q2
3/31/20230.15 0.12  (-20.58 %)2023 Q1
12/31/2022-0.13 -0.09  (28.34 %)2022 Q4
9/30/20220.19 0.23  (19.85 %)2022 Q3
6/30/20220.19 0.22  (15.36 %)2022 Q2
3/31/20220.15 0.21  (44.73 %)2022 Q1
1
2
3
4
5
...
10

Eulerpool ESG Scorecard© for the Exelixis stock

Eulerpool World ESG Rating (EESG©)

76/ 100

🌱 Environment

56

👫 Social

99

🏛️ Governance

73

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees53
Percentage of women in management—
Percentage of Asian employees39
Share of Asian management—
Percentage of Hispanic/Latino employees6
Hispano/Latino Management share—
Percentage of Black employees5
Black Management Share—
Percentage of white employees45
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Exelixis list of shareholders

%
Name
Stocks
Change
Date
9.33725 % Farallon Capital Management, L.L.C.26,634,500774,50012/31/2023
5.47440 % Renaissance Technologies LLC15,615,716398,80012/31/2023
4.56891 % State Street Global Advisors (US)13,032,818652,07412/31/2023
2.00236 % JP Morgan Asset Management5,711,731-290,09812/31/2023
11.08170 % The Vanguard Group, Inc.31,610,562-392,71712/31/2023
10.51682 % BlackRock Institutional Trust Company, N.A.29,999,220-748,45712/31/2023
1.80379 % Geode Capital Management, L.L.C.5,145,31870,57312/31/2023
1.59878 % Dimensional Fund Advisors, L.P.4,560,517-32,92412/31/2023
1.43967 % Stephens Investment Management Group, LLC4,106,664-88,92412/31/2023
1.21151 % T. Rowe Price Associates, Inc.3,455,844-819,76412/31/2023
1
2
3
4
5
...
10

Exelixis Executives and Management Board

Dr. Michael Morrissey62
Exelixis President, Chief Executive Officer, Director (since 2000)
Compensation 16.88 M
Mr. Christopher Senner55
Exelixis Chief Financial Officer, Executive Vice President
Compensation 5.18 M
Mr. Patrick Haley47
Exelixis Executive Vice President - Commercial
Compensation 4.65 M
Mr. Jeffrey Hessekiel54
Exelixis Executive Vice President, General Counsel, Secretary
Compensation 4.62 M
Dr. Stelios Papadopoulos74
Exelixis Independent Chairman of the Board, Co-Founder
Compensation 465,069
1
2
3
4

Most common questions regarding Exelixis

What values and corporate philosophy does Exelixis represent?

Exelixis Inc represents values of innovation, collaboration, and commitment to improving patients' lives. With a focus on discovering and developing small molecule drugs, the company strives for scientific excellence in bringing groundbreaking therapies to market. Exelixis Inc is dedicated to advancing the field of oncology with their portfolio of targeted medicines, addressing the unmet needs of cancer patients. By fostering partnerships and working closely with the medical community, Exelixis Inc believes in the power of collaboration to drive meaningful progress in the fight against cancer. Note: This answer contains 99 words.

In which countries and regions is Exelixis primarily present?

Exelixis Inc is primarily present in the United States, focusing on developing and commercializing innovative medicines. Based in Alameda, California, the company's operations extend across the nation. Exelixis Inc has established strategic partnerships and collaborations worldwide, engaging in research and development efforts with renowned institutions and organizations globally.

What significant milestones has the company Exelixis achieved?

Exelixis Inc, a renowned biotechnology company, has achieved significant milestones in its journey. Notably, the company secured a major breakthrough with the FDA approval of its flagship product, Cabometyx, for the treatment of advanced renal cell carcinoma. Additionally, Exelixis Inc successfully expanded Cabometyx's indications to include advanced hepatocellular carcinoma, solid tumors, and differentiated thyroid cancer. The company also witnessed positive clinical trial results, demonstrating the efficacy of Cabometyx in several cancer types. Exelixis Inc's continuous dedication to research and development has propelled it to become a leading name in the pharmaceutical industry, revolutionizing cancer treatment with groundbreaking therapies.

What is the history and background of the company Exelixis?

Exelixis Inc. is a biotechnology company founded in 1994, headquartered in Alameda, California. The company focuses on the discovery, development, and commercialization of novel therapies to treat cancer and other serious diseases. With a strong emphasis on precision medicine, Exelixis aims to improve patients' lives through targeted therapies. Throughout its history, Exelixis has made significant advancements in drug development and has brought several innovative medicines to market. Notably, the company's flagship product, CABOMETYX® (cabozantinib), has been approved for the treatment of various cancers. Exelixis continues to invest in research and development, collaborating with partners to expand its pipeline and deliver new treatments to patients worldwide.

Who are the main competitors of Exelixis in the market?

The main competitors of Exelixis Inc in the market are Bristol-Myers Squibb Co., Merck & Co. Inc., and Pfizer Inc.

In which industries is Exelixis primarily active?

Exelixis Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Exelixis?

The business model of Exelixis Inc is focused on the development, commercialization, and discovery of therapies for the treatment of cancer. The company primarily engages in the research and development of small molecule therapies, targeting specific pathways that contribute to the growth and spread of cancer cells. Exelixis Inc aims to bring innovative and effective cancer treatments to patients by leveraging its expertise in drug discovery and development. The company collaborates with various partners, including pharmaceutical companies and research institutions, to advance its pipeline of potential oncology treatments.

What is the P/E ratio of Exelixis 2024?

The Exelixis P/E ratio is 18.24.

What is the P/S ratio of Exelixis 2024?

The Exelixis P/S ratio is 3.99.

What is the AlleAktien quality score of Exelixis?

The AlleAktien quality score for Exelixis is 5/10.

What is the revenue of Exelixis 2024?

The expected Exelixis revenue is 2.09 B USD.

How high is the profit of Exelixis 2024?

The expected Exelixis profit is 457.4 M USD.

What is the business model of Exelixis

Exelixis Inc. is a biopharmaceutical company specializing in the research, development, and marketing of drugs for the treatment of cancer. The company is headquartered in Alameda, California, USA. The business model of Exelixis is based on three pillars: research and development, product marketing and licensing, and collaborations and partnerships with other pharmaceutical companies. Research and development involve the discovery of new compounds and therapies for the treatment of cancer. Exelixis specializes in identifying signaling pathways that are important for the survival and growth of tumor cells. The company has an extensive pipeline of cancer drugs in various stages of development. The most well-known product of Exelixis is Cabozantinib, which is approved for the treatment of kidney cancer and thyroid cancer. Exelixis markets its products through its own sales organization in the USA and through partnerships with other companies worldwide. The company aims to expand its presence in the USA and other countries to increase revenue and profits. Exelixis also works closely with other pharmaceutical companies to acquire licenses for new technologies and products, and to form partnerships for the joint development and marketing of drugs. These collaborations can help accelerate Exelixis' research and development efforts and bring its products to market faster. In summary, the business model of Exelixis Inc. is based on the research, development, and marketing of cancer drugs. The company engages in extensive research and development, has a pipeline of drugs in various stages of development, and collaborates with other companies to acquire new technologies and products and form partnerships for the joint development and marketing of drugs. Exelixis aims to expand its presence in the US and international markets to increase its revenue and profit.

What is the Exelixis dividend?

Exelixis pays a dividend of 0 USD distributed over payouts per year.

How often does Exelixis pay dividends?

The dividend cannot currently be calculated for Exelixis or the company does not pay out a dividend.

What is the Exelixis ISIN?

The ISIN of Exelixis is US30161Q1040.

What is the Exelixis WKN?

The WKN of Exelixis is 936718.

What is the Exelixis ticker?

The ticker of Exelixis is EXEL.

How much dividend does Exelixis pay?

Over the past 12 months, Exelixis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Exelixis is expected to pay a dividend of 0 USD.

What is the dividend yield of Exelixis?

The current dividend yield of Exelixis is .

When does Exelixis pay dividends?

Exelixis pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Exelixis?

Exelixis paid dividends every year for the past 0 years.

What is the dividend of Exelixis?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Exelixis located?

Exelixis is assigned to the 'Health' sector.

Wann musste ich die Aktien von Exelixis kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Exelixis from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Exelixis pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Exelixis in the year 2023?

In the year 2023, Exelixis distributed 0 USD as dividends.

In which currency does Exelixis pay out the dividend?

The dividends of Exelixis are distributed in USD.

All fundamentals about Exelixis

Our stock analysis for Exelixis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Exelixis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.